Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Healius Limited ( (AU:HLS) ) is now available.
Healius Limited has announced significant changes to its board, with the appointment of Professor Bruce Robinson as an independent Non-Executive Director and the retirement of Professor John Mattick. Professor Robinson, a distinguished physician and academic, brings extensive experience in healthcare leadership, which is expected to enhance the board’s capabilities. This transition reflects Healius’s strategic focus on strengthening its leadership in healthcare services, particularly in genomics diagnostics, and is likely to impact its operational strategies and stakeholder relations positively.
The most recent analyst rating on (AU:HLS) stock is a Hold with a A$1.05 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.
More about Healius Limited
Healius Limited operates in the healthcare industry, providing a range of medical services and diagnostics. The company focuses on delivering healthcare solutions, including genomics diagnostics, to enhance patient care and outcomes.
YTD Price Performance: -2.20%
Average Trading Volume: 2,566,649
Technical Sentiment Signal: Sell
Current Market Cap: A$711.6M
See more data about HLS stock on TipRanks’ Stock Analysis page.